OP

OpusPoint Partners

North America, New York, United States, New York

Description

OpusPoint Partners is a hedge fund that finances in publicly-traded biotech and life sciences companies.

Investor Profile

OpusPoint Partners has made 2 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Post Ipo Equity (50%)
  • Series Unknown (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Oncology
  • Pharmaceutical
  • Biopharma
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does OpusPoint Partners frequently co-invest with?

Nextech Invest
Europe, Zurich, Switzerland, Zürich
Co-Investments: 1
Bay City Capital
North America, California, United States, San Francisco
Co-Investments: 1
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 1
Dafna Capital Management
North America, California, United States, Los Angeles
Co-Investments: 1
VC
North America, New York, United States, New York
Co-Investments: 1
Alta Partners
North America, Mississippi, United States, Jackson
Co-Investments: 1
MN
North America, New York, United States, New York
Co-Investments: 1
BC
North America, New York, United States, New York
Co-Investments: 1
Venrock
North America, California, United States, Palo Alto
Co-Investments: 1
Caxton Advantage Life Sciences Fund
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by OpusPoint Partners?

Soligenix

Princeton, New Jersey, United States

Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.

BiopharmaBiotechnologyHealth CareMedical
Series UnknownJul 2, 2010
Amount Raised: $5,904,277
Sunesis Pharmaceuticals

South San Francisco, California, United States

Sunesis Pharmaceuticals is focused on the R&D of oncology therapeutics for the treatment of solid and hematologic cancers.

BiotechnologyHealth CareOncologyPharmaceutical
Post Ipo EquityApr 7, 2009
Amount Raised: $43,500,000